Stephen V Liu, MD· @StephenVLiu · X·· 2026-04-20Score60
Reading
KRAS / RAS targeting: from platform to Phase 3
zoldonrasib and VS-7375 in G12D remain Phase 1 — strong numbers, small samples, not head-to-head.
Body
#AACR26 Zoldonrasib in previously treated KRAS G12D NSCLC with RR 52%, DCR 93%, time to response 1.4m, mDOR not reached with median follow up of 13.1m, mPFS 11.1m, and 73% of pts with ctDNA clearance. Fantastic presentation, exciting drug for our patients!
Heat 15 · 9 likes · 1 reply · 5 reposts
Source: Stephen V Liu, MD · x.com